Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug therapy for urinary incontinence.

K E Andersson1

  • 1Department of Clinical Pharmacology, Lund University Hospital, Sweden.

Bailliere'S Best Practice & Research. Clinical Obstetrics & Gynaecology
|July 18, 2000
PubMed
Summary

Current urinary incontinence treatments primarily target peripheral systems, with limited central nervous system (CNS) options for storage disorders. New, targeted medications are needed to improve efficacy and reduce side effects for bladder overactivity and stress incontinence.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Calcium antagonists. Great tissue selectivity is the basis of their therapeutic use].

Lakartidningen·1997
Same author

Neurotransmitter release evoked by alpha-latrotoxin in the smooth muscle of the female pig urethra.

Naunyn-Schmiedeberg's archives of pharmacology·1997
Same author

NANC transmitters in the female pig urethra--localization and modulation of release via alpha 2-adrenoceptors and potassium channels.

British journal of pharmacology·1997
Same author

Morphological relations between haem oxygenases, NO-synthase and VIP in the canine and feline gastrointestinal tracts.

Journal of the autonomic nervous system·1997
Same author

Characterization of angiotensin II formation in human isolated bladder by selective inhibitors of ACE and human chymase: a functional and biochemical study.

British journal of pharmacology·1997
Same author

Stimulation of bladder activity by volume, L-dopa and capsaicin in normal conscious rats--effects of spinal alpha 1-adrenoceptor blockade.

Naunyn-Schmiedeberg's archives of pharmacology·1997

Area of Science:

  • Pharmacology
  • Urology
  • Drug Discovery

Background:

  • Urinary incontinence treatments predominantly act peripherally, with few central nervous system (CNS) agents available for urine storage disorders.
  • Current therapies for bladder overactivity include antimuscarinics, alpha- and beta-adrenoceptor antagonists/agonists, and prostaglandin synthesis inhibitors, often repurposed from other indications.

Purpose of the Study:

  • To review current pharmacological approaches for urinary incontinence, focusing on their sites of action (CNS vs. peripheral).
  • To evaluate the efficacy and limitations of existing drug classes for urge and stress incontinence.
  • To highlight the need for novel therapeutics specifically designed for urine storage disorders.

Main Methods:

  • Literature review of pharmacological agents used in urinary incontinence treatment.

Related Experiment Videos

  • Analysis of drug mechanisms, focusing on CNS and peripheral actions.
  • Assessment of current treatment standards and their associated side effects.

    • Main Results:

    • Most available drugs for urine storage disorders act peripherally.
    • Antimuscarinic drugs, particularly oxybutynin, are the current standard for urge incontinence despite significant side effects.
    • Pharmacological treatment for stress incontinence has shown limited success, with alpha-adrenoceptor agonists offering some benefit.

    Conclusions:

    • Existing treatments for urinary incontinence, especially urge and stress types, are suboptimal.
    • There is a clear unmet need for new drugs with targeted mechanisms for urine storage disorders.
    • Development of novel pharmacological agents is crucial for advancing the management of urinary incontinence.